Palatin Tech Stock Price, News & Analysis

Palatin Technologies (NYSE American: PTN) announced the filing of an international patent application for PL9643, aimed at treating Dry Eye Disease (DED). Positive Phase 2 study results will be shared at the ARVO 2021 meeting, with a Phase 2/3 trial planned for mid-2021. If granted, the patent could protect PL9643 until 2041. Dry Eye Disease affects over 20 million Americans, causing significant discomfort and potential vision issues. Palatin aims to develop first-in-class medicines targeting unmet medical needs, seeking partnerships to enhance commercialization efforts.

Palatin Technologies (PTN) announced positive results from its Phase 2 study of PL9643 for treating moderate to severe dry eye disease (DED). The trial showed significant improvement in multiple ocular signs and symptoms after 2 weeks and at the 12-week mark for the specific moderate to severe patient population, although overall primary endpoints were not met. No safety issues arose, and PL9643 demonstrated excellent ocular tolerability. Palatin plans to advance to a Phase 2/3 trial in mid-2021, targeting the approximately 20 million adults suffering from DED in the U.S.

Palatin Technologies, Inc. (PTN) reported a net loss of $3.9 million for Q1 2020, down from $4.5 million in Q1 2019. Vyleesi® gross sales reached $809,100, with recognized revenue of $(288,560). Total operating expenses decreased to $3.7 million. The company had $86.6 million in cash and equivalents as of September 30, 2020. Palatin regained North American rights to Vyleesi, enhancing commercial activities and initiating a targeted marketing campaign. Upcoming data readout for PL9643 Phase 2 clinical trial is expected in December 2020.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2021 operating results on November 17, 2020, prior to market opening. A conference call led by executive management will follow at 11:00 a.m. ET, covering operational updates and program developments. The results will be reported via a press release at 7:30 a.m. ET the same day. Audio webcasts for both the call and the replay will be accessible on Palatin's website for investors.

Palatin Technologies (PTN) reported a net loss of $(7.3) million for Q4 FY2020, reversing from a net income of $52.2 million in Q4 FY2019. The total net loss for the fiscal year was $(22.4) million, compared to $35.8 million net income in FY2019. The decline is attributed to a lack of license revenue recognized from AMAG, which was $60.3 million in the previous year. As of June 30, 2020, Palatin holds $82.9 million in cash and is debt-free. The Company plans to advance its clinical programs, including PL9643 for dry eye disease, with topline data expected in Q4 2020.

Palatin Technologies (PTN) will announce its fourth quarter and fiscal year end 2020 operating results on September 28, 2020, before the U.S. market opens. A conference call and live audio webcast will follow at 11:00 a.m. ET on the same day, where management will discuss the operating results and provide updates on ongoing programs. Financial results and access details will be available through Palatin's website, ensuring broad accessibility for investors and stakeholders.

Palatin Technologies, Inc. (NYSE American: PTN) announced its participation in the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020, at 4:00 p.m. EDT, through a virtual presentation. Carl Spana, President and CEO, will discuss the company's corporate and development updates. Interested parties can access the webcast via the official website or by following the provided link. The presentation will be available for replay for 90 days.

Palatin Technologies, Inc. (NYSE American: PTN) participated in Canaccord Genuity's 40th Annual Growth Conference on August 13, 2020, engaging in a Fireside Chat hosted by John Newman. CEO Carl Spana and CFO Stephen T. Wills represented the company during the virtual event. The discussion focused on Palatin's specialized biopharmaceutical developments, particularly its first-in-class medicines targeting melanocortin and natriuretic peptide receptor systems. A webcast replay is available on the company's website for 90 days.

Palatin Technologies (NYSE American: PTN) announced the completion of patient enrollment for its Phase 2 study of PL9643 aimed at treating dry eye disease (DED). The study, which resumed enrollment after COVID-19 delays, aims to evaluate PL9643's efficacy and safety compared to a placebo. With data readout expected in Q4 2020, Palatin emphasizes the potential of PL9643 to offer a quick onset of efficacy and a favorable safety profile, addressing the needs of patients who struggle with existing therapies for DED.